このページの翻訳は実験的なもので、現在開発中です。お待ちしております
EyePoint Pharmaceuticals マネジメント
マネジメント 基準チェック /24
EyePoint Pharmaceuticals'の CEO はJay Dukerで、 Jan2023年に任命され、 の在任期間は 1.58年です。 の年間総報酬は$ 2.92Mで、 21.1%給与と78.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.11%を直接所有しており、その価値は$ 467.28K 。経営陣と取締役会の平均在任期間はそれぞれ1.6年と3年です。
主要情報
Jay Duker
最高経営責任者
US$2.9m
報酬総額
| CEO給与比率 | 21.1% |
| CEO在任期間 | 1.7yrs |
| CEOの所有権 | 0.1% |
| 経営陣の平均在職期間 | 1.7yrs |
| 取締役会の平均在任期間 | 3.1yrs |
経営陣の近況
Recent updates
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price
Sep 13
EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)
Aug 29These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Aug 15EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 09Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%
Jun 19EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
May 06More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
Mar 31EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
Feb 20Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%
Feb 05Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?
Jan 29Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking
Dec 18These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Dec 13Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
May 14Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking
Apr 17EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space
Aug 30Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Jul 16EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD
Jul 15Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Mar 06EyePoint Pharmaceuticals (NASDAQ:EYPT) Is Using Debt Safely
Sep 24Estimating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Apr 02CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$87m |
| Mar 31 2024 | n/a | n/a | -US$79m |
| Dec 31 2023 | US$3m | US$614k | -US$71m |
| Sep 30 2023 | n/a | n/a | -US$100m |
| Jun 30 2023 | n/a | n/a | -US$106m |
| Mar 31 2023 | n/a | n/a | -US$102m |
| Dec 31 2022 | US$2m | US$515k | -US$102m |
| Sep 30 2022 | n/a | n/a | -US$78m |
| Jun 30 2022 | n/a | n/a | -US$77m |
| Mar 31 2022 | n/a | n/a | -US$67m |
| Dec 31 2021 | US$3m | US$269k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$54m |
| Jun 30 2021 | n/a | n/a | -US$42m |
| Mar 31 2021 | n/a | n/a | -US$44m |
| Dec 31 2020 | US$53k | n/a | -US$45m |
| Sep 30 2020 | n/a | n/a | -US$40m |
| Jun 30 2020 | n/a | n/a | -US$52m |
| Mar 31 2020 | n/a | n/a | -US$51m |
| Dec 31 2019 | US$80k | n/a | -US$57m |
| Sep 30 2019 | n/a | n/a | -US$58m |
| Jun 30 2019 | n/a | n/a | -US$75m |
| Mar 31 2019 | n/a | n/a | -US$98m |
| Dec 31 2018 | US$27k | n/a | -US$86m |
報酬と市場: Jayの 総報酬 ($USD 2.92M ) は、 US市場 ($USD 2.41M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Jayの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Jay Duker (65 yo)
1.7yrs
在職期間
US$2,915,146
報酬
Dr. Jay S. Duker, M.D., co-founded Hemera Biosciences Inc. and serves as its Executive Director. He serves as Member of Retina Segment Scientific Advisory Board at Aldeyra Therapeutics, Inc. He served as C...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 1.7yrs | US$2.92m | 0.11% $ 488.5k | |
| Executive VP & CFO | 4.8yrs | US$1.78m | 0.089% $ 383.2k | |
| Interim Head of R&D and Director | less than a year | US$161.67k | 0.021% $ 92.0k | |
| Senior Vice President of Manufacturing & Operations | 1.2yrs | データなし | データなし | |
| Chief Legal Officer & Company Secretary | 5.8yrs | データなし | データなし | |
| Chief People Officer & Senior VP of IT | 5.7yrs | データなし | データなし | |
| Senior VP & Chief Commercial Officer | 5.3yrs | US$1.46m | 0% $ 0 | |
| Chief Business Officer | less than a year | US$1.61m | 0.026% $ 110.3k | |
| Chief Regulatory Officer | 2.5yrs | データなし | データなし | |
| Senior VP and Head of Development & Program Management | 1.2yrs | データなし | データなし | |
| Chief Medical Officer | less than a year | データなし | データなし | |
| CEO of AION Diagnostics Ltd | no data | US$225.94k | データなし |
1.7yrs
平均在職期間
58yo
平均年齢
経験豊富な経営陣: EYPTの経営陣は 経験豊富 とはみなされません ( 1.6年の平均在職年数)。これは新しいチームを示唆しています。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 1.2yrs | US$2.92m | 0.11% $ 488.5k | |
| Interim Head of R&D and Director | 5.9yrs | US$161.67k | 0.021% $ 92.0k | |
| CEO of AION Diagnostics Ltd | no data | US$225.94k | データなし | |
| Independent Non-Executive Chairman | 6.3yrs | US$214.78k | 0.025% $ 106.1k | |
| Independent Director | 5.2yrs | US$171.67k | 0.019% $ 80.4k | |
| Vice Chair | 8yrs | US$3.74m | 0.42% $ 1.8m | |
| Co- Chairman of Scientific Advisory Board | 3.1yrs | データなし | データなし | |
| Member of Executive Scientific Advisory Board | 3.1yrs | データなし | データなし | |
| Independent Director | 2.2yrs | US$149.17k | 0.031% $ 133.2k | |
| Co-Chair of Scientific Advisory Board | 3.1yrs | データなし | データなし | |
| Member of Executive Scientific Advisory Board | 3.1yrs | データなし | データなし | |
| Member of Executive Scientific Advisory Board | 3.1yrs | データなし | データなし |
3.1yrs
平均在職期間
66yo
平均年齢
経験豊富なボード: EYPTの 取締役会 は 経験豊富 であると考えられます ( 3年の平均在任期間)。